US 9,809,575 B2
Pharmaceutical compounds
Stuart Cockerill, London (GB); Christopher Pilkington, London (GB); James Lumley, London (GB); Richard Angell, London (GB); and Neil Mathews, London (GB)
Assigned to ReViral Limited, Stevenage (GB)
Appl. No. 14/357,293
Filed by re:Viral Ltd, London (GB)
PCT Filed Nov. 12, 2012, PCT No. PCT/GB2012/052806
§ 371(c)(1), (2) Date May 9, 2014,
PCT Pub. No. WO2013/068769, PCT Pub. Date May 16, 2013.
Claims priority of application No. 1119538.5 (GB), filed on Nov. 10, 2011.
Prior Publication US 2014/0308282 A1, Oct. 16, 2014
Int. Cl. C07D 403/06 (2006.01); A61K 31/4184 (2006.01); A61K 31/437 (2006.01); A61K 31/4747 (2006.01); A61K 31/5386 (2006.01); C07D 401/06 (2006.01); C07D 413/06 (2006.01); C07D 471/10 (2006.01); A61K 31/5513 (2006.01); A61K 45/06 (2006.01); C07D 498/10 (2006.01)
CPC C07D 403/06 (2013.01) [A61K 31/4184 (2013.01); A61K 31/437 (2013.01); A61K 31/4747 (2013.01); A61K 31/5386 (2013.01); A61K 31/5513 (2013.01); A61K 45/06 (2013.01); C07D 401/06 (2013.01); C07D 413/06 (2013.01); C07D 471/10 (2013.01); C07D 498/10 (2013.01)] 10 Claims
 
1. A compound which is a benzimidazole of formula (I):

OG Complex Work Unit Drawing
wherein:
A is phenyl or 6-membered heteroaryl, each of which is unsubstituted or substituted by 1, 2 or 3 groups Q;
Y is a single bond, —O—, —C(═O)—N(R2)—, or —(CH2)p—;
each L is independently C1-3 alkylene;
R1 is linear or branched C1-6 alkyl, which is unsubstituted or substituted by 1, 2 or 3 groups Q;
each Z is independently —N(R2)2 or —OR2;
each R2 is independently hydrogen or C1-4 alkyl;
m is 0 or 1;
n is 1, 2, or 3;
p is 1 or 2; and
Q is halo, nitro, —CN, OH, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 alkylthio, C1-6 haloalkyl, C1-4 haloalkoxy, —CO2R′″, —NR′″2, —SR′″, —S(═O)R′″ or —S(═O)2R′″, wherein each R′″ is independently selected from H and C1-6 alkyl;
or a pharmaceutically acceptable salt thereof.